PRESS RELEASENantes, September 25th, 2026 H1 2026 Results: Continued cost discipline and balance sheet  restoration amidst a persistently challenging top-line environment  Reminder: since July 2026, the Group has been operating with a strengthened balance sheet following the refinancing agreement reached with its main stakeholders. Full details are available in the press release dated July 31, 2026.  Net sales reached €412.8m, down 7.1% vs LY (-5.8% LfL) in a subdued market  €15m gross savings achieved Working Capital improvementNet Sales reached €412.8m, down 7.1% YoY (-5.8% on a LfL basis):Performance contracted further in Q2 (-9.8%) compared to Q1 (-4.5%), impacted by constrained inventory levels and a deliberate scale-back of promotional activities  The store network keeps proving resilience at -3.0% LfL. Southern Europe remained...

AUSTIN, Texas, Sept. 25, 2026 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the fiscal year ended June 30, 2026. Financial Highlights & Fiscal Year Developments As of June 30, 2026, the Company had deployed the TRACER 1000 in approximately 37 locations in 16 countries across the United States, Europe and Asia.The Company launched its Labrador ruggedized Handheld Gas Chromatograph designed to bring laboratory-grade volatile organic compound analysis directly to the point of investigation.The Board of Directors of the Company approved a strategic initiative focused on potential future lunar resource development, autonomous lunar industrial infrastructure, Moon based advanced computing, semiconductor, manufacturing, lunar power generation and power...

LIBERTY, Mo., Sept. 25, 2026 (GLOBE NEWSWIRE) — Ferrellgas Partners, L.P. (OTC: FGPR) (“Ferrellgas” or the “Company”) today reported financial results for its fourth fiscal quarter and fiscal year (“fiscal 2026”) ended July 31, 2026. “Ferrellgas closed out fiscal 2026 with real momentum,” said Tamria Zertuche, President and CEO. “Fourth quarter Adjusted EBITDA grew 3% over the prior year, and while fiscal 2026 Adjusted EBITDA decreased 3%, primarily due to the settlement of several legacy general liability claims, our employee-owners generated $321.3 million of Adjusted EBITDA. Additionally, we refinanced a portion of our balance sheet, earned credit rating upgrades from both S&P Global and Moody’s, and completed the conversion of our Class B Units into Class A Units, simplifying our capital structure for the long term. These...

CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) — Bango (AIM: BGO), the global platform for subscription bundling and payments, today announces its unaudited Interim Results for the six months ended 30 June 2026. Financial overview (unaudited):  1H26 1H25 ChangeRevenue      Payments1 $13.6M $14.3M -5%Subscriptions2 $12.3M $10.9M +13%Total $25.9M $25.2M +3%       Adj EBITDA3      Payments $5.8M $5.7M +1%Subscriptions $3.2M $1.0M +224%Total $9.0M $6.7M +34%       Cash EBITDA4      Payments  $4.7M $4.6M  +$0.1MSubscriptions  ($1.0M) ($5.3M)  +$4.3M Total $3.7M ($0.7M) +$4.3M        Annual Recurring Revenue (ARR)5 $20.4M $15.6M +31%Net Revenue Retention (NRR)6 119% 108%           30 June 2026 31 Dec 2025  Net debt7 $8.7M $9.2M -$0.5M       HighlightsARR...

Cash and cash equivalents of €12.3 million as of June 30, 2026, a 2.4-fold increase compared to December 31, 2025 (€5.1 million), following the €15 million capital increase completed in May. Shareholders’ equity returned to positive territory at €3.0 million (compared to −€4.9 million as of December 31, 2025), and adjusted net financial debt was more than halved to €7.8 million (from €17.4 million). BARDA revenue totaled €2.5 million (€6.6 million in H1 2025), as H1 2025 saw a concentration of validation activities and a clinical trial; H1 2026 returned to a pace representative of ongoing development activity. Operating expenses remained stable at €10.3 million, excluding depreciation, provisions, and disposal-related items (€10.3 million in H1 2025). Net income of −€8.6 million (−€4.9 million in H1 2025): H1 2025 saw two non-recurring...

Manpower Outsourcing Revenue Increased 62.4% to US$15.6 Million; Integrated Facility Management Revenue Increased 11.1% to US$16.1 Million Net Loss Narrowed 13.8% Year Over Year Working Capital Improved to US$11.9 Million from a Deficit of US$1.7 Million at Year-End 2025; Total Liabilities Reduced 39% SINGAPORE, Sept. 24, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (Nasdaq: YFOR) (“YYForce” or the “Company,” formerly YY Group Holding Limited (Nasdaq: YYGH)), an AI-enabled workforce management platform and integrated facility management (IFM) provider operating across Asia and beyond, today announced its unaudited financial results for the six months ended June 30, 2026. YYForce reported first-half 2026 revenue of approximately US$32.7 million, an increase of 26.8% from US$25.8 million for the corresponding period...

Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation Strengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029 Acceptable safety profile and promising initial efficacy responses observed in Johnson & Johnson-led Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in Stage 3 unresectable NSCLC U.S. FDA clearance for protocol amendment to the Johnson & Johnson-led Phase 3 NANORAY-312 study evaluating JNJ-1900 (NBTXR3) in locally advanced platinum ineligible head and neck cancer €110.9 million in cash and cash equivalents...

ISSAQUAH, Wash., Sept. 24, 2026 (GLOBE NEWSWIRE) — Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the 16-week fourth quarter and the 52-week fiscal year ended August 30, 2026. Net sales for the quarter increased 11.2 percent, to $93.9 billion, from $84.4 billion last year. Net sales for the fiscal year increased 10.1 percent, to $297.2 billion, from $269.9 billion last year. Comparable sales for the fourth quarter and fiscal year were as follows:  16 Weeks   16 Weeks   52 Weeks   52 Weeks      Adjusted*       Adjusted*U.S. 10.7%   7.2%   8.2%   6.6%Canada 5.0%   4.6%   7.8%   6.7%Other International 7.0%   6.2%   9.8%   6.5%               Total Company 9.4%   6.7%   8.4%   6.6%               Digitally-Enabled 19.5%   19.8%   20.9%   20.7%*Excluding...

REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026. Tumor HIupLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumor HI, is ongoing.Enrollment is in progress and topline results are expected before the end of 2026.In June 2026, the Company shared positive interim data from the upLIFT study, announcing that of the 8 participants enrolled, 6 had already met the responder criterion for the study’s primary endpoint within the 8-week pivotal treatment...

ROBERTET GROUP – INTERIM CONSOLIDATED FINANCIAL STATEMENTS – HALF-YEAR 2026AttachmentROBERTET-RFS-EN_2026